

Cardiopulmonary and Renal Risk Factors for Pulmonary Hypertension in Sickle Cell Disease

Thesis

*Submitted for the partial fulfillment of the
M.D degree in Pediatrics*

Presented By

Marwa Abd Elhady Abd Elsamad Deabes

*Assistant Lecturer of Pediatrics
Faculty of Medicine - Cairo University*

Supervised by

Prof. Dr. Mona Hassan El Tagui

*Professor of Pediatrics
Faculty of Medicine - Cairo University*

Prof. Dr. Hala Mounir Agha

*Professor of Pediatrics
Faculty of Medicine - Cairo University*

Prof. Dr. Fatma Ahmed Fathy El Mougny

*Professor of Chemical Pathology
Faculty of Medicine - Cairo University*

Prof. Dr. Mona Kamal El Ghamrawy

*Assistant Professor of Pediatrics
Faculty of Medicine - Cairo University*

**Faculty of Medicine
Cairo University**

٢٠١٢

عوامل الخطورة القلبية والرئوية والكلى لارتفاع ضغط الشريان الرئوى فى مرض الخلايا المنجلية

توطئة للحصول على درجة الدكتوراه

فى طب الأطفال

مقدمه من الطيبة

مروة عبد المادى عبد الصمد دمحس

مدرس مساعد طب الاطفال

كلية الطب - جامعة القاهرة

تحت إشراف

أ.د / منى حسن التاجى

أستاذ طب الأطفال

كلية الطب - جامعة القاهرة

أ.د/ هالة منير أغا

أستاذ طب الاطفال

كلية الطب - جامعة القاهرة

أ. د/ فاطمة أحمد فتحي الموجي

أستاذ الباثولوجية الكيميائية

كلية الطب - جامعة القاهرة

د/ منى كمال الغمراوي

أستاذ مساعد طب الاطفال

كلية الطب - جامعة القاهرة

كلية الطب - جامعة القاهرة

٢٠١٢

List of Abbreviations

ACS	Acute Chest Syndrome
ADMA	Asymmetric Dimethylarginine
AHRQ	Agency for Healthcare Research and Quality
ANP	Atrial Natriuretic Peptide
AO	Aortic diameter
ATS	American Thoracic Society
AVN	Avascular Necrosis of Hip and Shoulder
CBC	Complete Blood Picture
cGMP	cyclic Guanosine Monophosphate
COPD	Chronic Obstructive Pulmonary Disease
CRP	C –Reactive Protein
CSF	Cerebrospinal Fluid
CSSCD	Cooperative Study of Sickle Cell Disease
CT	Computed Tomography
CVS	Chorionic villous Sampling
DBP	Diastolic Blood pressure
DDAH	Dimethylarginine Dimethylaminohydrolase
EF	Ejection Fraction
EPCs	Endothelial Progenitor Cells
ESRD	End-Stage Renal Disease
ET-1	Endothelin-1
FS	Fraction Shortening
GFR	Glomerular Filtration Rate
GM-CSF	Granulocyte Monocyte Colony Stimulating Factor
GTP	Guanosine Triphosphate
HCT	Haemopoietic Cell Transplantation
HDAC	Histone Deacetylase
HDL-C	High-Density Lipoprotein Cholesterol
HIV	Human Immunodeficiency Virus
HLA	Human Leucocytic Antigen
HPLC	High Performance Liquid Chromatography
HR	Heart Rate
IPAH	Idiopathic Pulmonary Arterial Hypertension
IVS	Interventricular Septum Diameter
LA	Left atrial diameter
LA/AO	Left Atrial Diameter/Aortic diameter
LDH	Lactate Dehydrogenase
LVEDD	Left Ventricular End –Diastolic Diameter
LVEDV	Left Ventricular End Diastolic Volume
LVESD	Left Ventricular End Systolic Diameter

LVESV	Left Ventricular End Systolic Volume
LVPW	Left Ventricular Posterior Wall
MBP	Mean Blood Pressure
MCV	Mean Corpuscular Volume
MRI	Magnetic Resonance Imaging
NFKB	Nuclear Factor KB
NIH	National Institutes of Health
NSAID	Nonsteroidal Anti-Inflammatory Drug
NT-proBNP	N-Terminal Pro-brain Natriuretic Peptide
NYHA	New York Heart Association
PA	Pulmonary artery
PAH	Pulmonary Arterial Hypertension
PAP	Pulmonary Artery Pressure
PASP	Pulmonary Artery Systolic Pressure
PCV^v	^v -Valent Pneumococcal Conjugate Vaccine
PDE-^o	Phosphodiesterase- ^o
PGD	Preimplantation Genetic Diagnosis
PHT	Pulmonary Hypertension
PIGF	Placental Growth factor
PS	Phosphatidylserine
ROS	Reactive Oxygen Species
RV	Right ventricle
RVEF	Right Ventricle Ejection Fraction
RVSP	Right Ventricular Systolic Pressure
SBP	Systolic Blood Pressure
SCD	Sickle Cell Disease
sFLT-¹	Soluble Fms-like tyrosine kinase- ¹
¹-MWD	¹ -Minute-walk distance
¹-MWT	¹ -Minute-walk test
TIAS	Transient Ischemic Attacks
TRG	Tricuspid Regurgitant Gradient
TRV	Tricuspid Regurgitant Jet Velocity
VCAM	Vascular Endothelial Cell Adhesion Molecule
VEGFR	Vascular Endothelial Growth Factor Receptor
VOC	Vaso-Occlusive crisis
WHO	World Health Organization

List of Figures

	Page
Fig. (١) Inheritance of sickle cell disease	٥
Fig. (٢) Mechanism of vasculopathy in SCD	٨
Fig. (٣) Intravascular hemolysis and the phenotypes of SCD	١١
Fig. (٤) Spectrum of sickle cell complications	١٥
Fig. (٥) Peripheral blood smear of a patient with hemoglobin SS	٢٥
Fig. (٦) Pathogenesis of pulmonary hypertension in SCD	٥١
Fig. (٧) Histologic appearance of pulmonary vessels from a patient with SCD and previously undetected pulmonary hypertension	٥٧
Fig. (٨) Hypothetical model of the progression of pulmonary arterial hypertension during childhood and adulthood in patients with SCD	٥٨
Fig. (٩) Diagnostic algorithm for the evaluation of pulmonary hypertension associated with sickle cell disease	٦٩
Fig. (١٠) Treatment algorithm in patients with sickle cell disease and pulmonary hypertension	٧٨
Fig. (١١) Sex distribution among the SCD population	١٠٤
Fig. (١٢) Genotype distribution among the SCD patients	١٠٤
Fig. (١٣) Complications of SCD among the studied patients	١٠٦
Fig. (١٤) Renal symptoms among the studied patients	١٠٦
Fig. (١٥) Hydroxyurea therapy in the studied SCD patients	١٠٨
Fig. (١٦) Prevalence of pulmonary hypertension among the patients	١١٤
Fig. (١٧) Distribution of the TRV among the studied patients	١١٤
Fig. (١٨) Sex and the genotype distribution of the two groups	١١٦
Fig. (١٩a) Complications of SCD of the two groups	١١٩
Fig. (١٩b) Cardiopulmonary symptoms of the two groups	١١٩
Fig. (٢٠) Distribution of treatment among the two groups	١٢٢
Fig. (٢١) Cardiac and abdominal examination of the two groups	١٢٤
Fig. (٢٢) Platelet count,LDH,ferritin level of the two groups	١٢٦
Fig. (٢٣) WBC, Hb, Retics and HbF of the two groups	١٢٧
Fig. (٢٤) Correlation of the tricuspid regurgitant jet velocity with the age	١٣٠
Fig. (٢٥) Correlation of the tricuspid regurgitant jet velocity the duration of the disease	١٣١
Fig. (٢٦) Correlation of the tricuspid regurgitant jet velocity with Hb (g/dl) concentration	١٣٣
Fig. (٢٧) Correlation of the tricuspid regurgitant jet velocity with reticulocytic count (%)	١٣٣
Fig. (٢٨) Correlation of the tricuspid regurgitant jet velocity with LDH (U/L) levels	١٣٤
Fig. (٢٩) Correlation of the tricuspid regurgitant jet velocity with serum ferritin (ng/ml) levels	١٣٤
Fig. (٣٠) Correlation of the tricuspid regurgitant jet velocity with creatinine (mg/dl) level	١٣٥
Fig. (٣١) Correlation of the Hb (gm/dl) with albumin/creatinine (microalbuminuria)	١٣٥
Fig. (٣٢) Correlation of the tricuspid regurgitant jet velocity with the distance walked	١٣٧

		Page
Fig. (۳۳)	Correlation of the tricuspid regurgitant jet with systolic blood pressure (mmHg) pre	۱۳۷
Fig. (۳۴)	Correlation of the tricuspid regurgitant jet velocity with O _۲ saturation (%) pre	۱۳۸
Fig. (۳۵)	Correlation of the tricuspid regurgitant jet velocity with right ventricle	۱۳۹
Fig. (۳۶)	Correlation of the tricuspid regurgitant jet velocity with pulmonary artery	۱۳۹
Fig. (۳۷)	Correlation of the systolic blood pressure (mmHg) with the the interventricular septum thickness	۱۴۰
Fig. (۳۸)	Correlation of the Hb (g/dl) with LA/AO ratio	۱۴۲
Fig. (۳۹)	Correlation of the Hb (g/dl) with PASP (mmHg)	۱۴۲

List of Tables

	Page
Table (١) Common genotypes of sickle cell disease	٧
Table (٢) Indications for episodic blood transfusion in patients with sickle cell disease	٢٨
Table (٣) Indications for chronic blood transfusion in patients with sickle cell disease	٢٩
Table (٤) Potential laboratory and clinical indications for hydroxyurea treatment in patients with SCD	٣١
Table (٥) Baseline work-up required by the consulting hematologist before hydroxyurea treatment initiation	٣٤
Table (٦) Vascular effect of No	٥٣
Table (٧) Factors linked epidemiologically to PHT in SCD	٦٠
Table (٨) WHO functional classification for patients with PHT	٦٤
Table (٩) Pharmacologic agents approved for use in pulmonary arterial hypertension	٨٣
Table (١٠) Indications for six minute walk test	٩١
Table (١١) The Borg scale	٩٢
Table (١٢) Factors that affect ٦-Minute walk Distance	٩٣
Table (١٣) The normal values of GFR	٩٨
Table (١٤) Values of albumin /creatinine ratio	٩٩
Table (١٥) Demographic data of the patients with SCD	١٠٤
Table (١٦) Clinical characteristics of the patients	١٠٥
Table (١٧) Treatment and blood transfusion therapy of the patients	١٠٨
Table (١٨) Dose and duration of hydroxyurea and chelation therapy	١٠٨
Table (١٩) Growth parameters, heart rate and blood pressure of the studied patients	١٠٩
Table (٢٠) General and local examination of the studied patients	١١٠
Table (٢١) Laboratory results of the studied patients	١١١
Table (٢٢) Glomerular filtration rate of the studied patients	١١١
Table (٢٣) Dimensional and M-mode echocardiographic data of the studied patients	١١٣
Table (٢٤a) Demographic data of the two groups of patients	١١٥
Table (٢٤b) Demographic data of the two groups of patients	١١٦
Table (٢٥) Clinical characteristics of the two groups of patients	١١٨
Table (٢٦) Comparison between the two groups as regards treatment and transfusion therapy	١٢٠
Table (٢٧a) Comparison between the two groups as regards compliance and duration of hydroxyurea therapy	١٢١
Table (٢٧b) Comparison between the two groups as regards compliance to hydroxyurea	١٢١
Table (٢٨) Comparison between the two groups as regards the dose hydroxyurea and chelation therapy	١٢٢
Table (٢٩) Comparison between the two groups as regards general and local examination	١٢٣
Table (٣٠) Comparison between the two groups as regards the laboratory parameters	١٢٥
Table (٣١) Comparison between the two groups as regards microalbuminuria	١٢٦
Table (٣٢) Comparison between the two groups as regards GFR	١٢٦

	Page
Table (٣٣) Comparison between the two groups as regards the Echocardiographic parameters	١٢٨
Table (٣٤) Comparison in ٦MWT data between the studied patients & the control group	١٢٩
Table (٣٥) Correlation of the tricuspid regurgitant jet velocity with the age and the duration of the disease	١٣٠
Table (٣٦) Correlation of the tricuspid regurgitant jet velocity with the laboratory variables of the patients	١٣٢
Table (٣٧) Correlation of the albumin creatinine ratio (microalbuminuria) with the hemoglobin level	١٣٢
Table (٣٨) Correlation of the tricuspid regurgitant jet velocity with the items of the six minute walk test	١٣٦
Table (٣٩) Correlation of the tricuspid regurgitaant jet velocity with the right ventricle and the pulmonary artery diameter	١٣٨
Table (٤٠) Correlation of the systolic blood pressure with the left ventricular posterior wall and the interventricular septum diameter	١٤٠
Table (٤١) Correlation of hemoglobin level with the different parameters of Echocardiography	١٤١
Table (٤٢) Independent predictors of increased tricuspid regurgitation velocity by multiple linear regression analysis	١٤٣

CONTENTS

List of Abbreviations.....	A
List of Tables	C
List of Figures.....	E
Introduction and Aim of the Work	١
Review of Literature	٥
Chapter I: Sickle Cell Disease	٥
Chapter II: Sickle Nephropathy and Pulmonary Hypertension	٤٤
Chapter III: Pulmonary Hypertension in Sickle Cell Disease	٥٠
Chapter IV: Six Minute Walk Test	٨٩
Subjects & Methods	٩٥
Results.....	١٠٣
Discussion.....	١٤٤
Conclusions & Recommendations	١٦٢
Summary	١٦٤
References.....	١٦٧
Arabic Summary	

Acknowledgement

*First and foremost thanks to **God**, The kindest and the most merciful.*

*I wish to express my sincere gratitude and utmost thanks to **Dr. Mona Hassan El Tagui**, Professor of Pediatrics, Faculty of Medicine, Cairo University, for her continuous encouragement, valuable advice and kind supervision throughout this work.*

*I am also extremely grateful to **Dr. Hala Mounir Agha** Professor of Pediatrics, Faculty of Medicine, Cairo University, for her continuous help, support, supervision and guidance.*


*I am grateful to **Dr. Fatma Ahmed Fathy El Mogui** Professor of Chemical Pathology, Faculty of Medicine, Cairo University, for her effort, supervision and assistance.*

*I am also sincerely thankful **Dr. Mona Kamal El Ghamrawy**, Assistant Professor of Pediatrics, Faculty of Medicine, Cairo University, for her valuable suggestions, advice and constructive supervision throughout this work.*

*Many thanks for **Dr. Amal Mahmoud Elsisy** Professor of Pediatrics, Faculty of Medicine, Cairo University for her help in conducting this study.*

My thanks to my family for her generous patience and support

Last but not least many thanks to our patients and their families.



Introduction

Pulmonary hypertension (PHT) is an ominous complication in patients with sickle cell disease (SCD) with a reported prevalence ranging from 30 to 40 % (*Ataga et al., 2004; De Castro et al., 2004*).

The pathogenesis of PHT complicating SCD is probably heterogeneous, including hemolysis and its effect on nitric oxide bioavailability, asplenia, thrombosis, chronic lung disease, and iron overload (*Lee et al., 2004*).

Echocardiographic estimation of pulmonary artery pressure by measuring the tricuspid valve regurgitant jet velocity (TRV) has been validated as a useful screening method for pulmonary hypertension in adult patients with sickle cell disease (*Gladwin et al., 2004*). A jet velocity of 3.0 m/sec or more, which corresponds to a systolic pulmonary artery pressure of 30 mmHg or more, has been used for research purposes to define elevated pulmonary artery pressure in adults with sickle cell disease (*Ataga et al., 2004; Castro & Gladwin., 2004*). Even though this definition includes mild elevations in pulmonary artery pressure, adult sickle cell disease patients with a regurgitant jet velocity of 3.0 m/sec or more have an increased risk of mortality (*De Castro et al., 2004*). SCD patients with PHT had a 40-month mortality rate of 40% compared with <3% for those without PHT. This increased risk of death occurs despite milder elevations of pulmonary artery pressure, lower pulmonary vascular resistance, and higher cardiac output than are observed in patients with idiopathic or other forms of secondary PHT (*Machado & Gladwin., 2004*).

Whether PHT is a direct cause of death in SCD or is a manifestation of multi-organ disease from systemic vasculopathy remains uncertain (*Kato et al., 2004; Klings., 2004*).

In children with SCD, reports indicate that PHT also occurs with a similar prevalence of about 30%, but the prognostic significance and natural history of PHT in children with SCD are unknown (*Kato et al., 2007*).

Epidemiologic risk factors suggested to be associated with PHT in patients with SCD include the following: low hemoglobin levels, high reticulocytic count suggestive of more severe hemolytic anemia; high steady-state serum lactate dehydrogenase (LDH) level, largely reflecting intravascular hemolysis (*Kato et al., 2007*) high serum creatinine levels, indicative of renal insufficiency; high serum direct bilirubin and alkaline phosphatase levels, suggesting cholestatic hepatic dysfunction and low serum transferrin or high serum ferritin levels, indicative of iron overload (*Gladwin et al., 2004*) In addition, the prevalence of an elevated TRV appears to rise with age during adulthood, exceeding 60% after 50 years of age (*Ataga et al., 2004; Gladwin et al., 2004*) One study had conflicting findings regarding the relationship of high TRV to systolic blood pressure (*Ataga et al., 2004*) Another has found an additional correlation of high TRV to proteinuria (*De Castro et al., 2004*). Elevated TRV is also associated with abnormal 6-minute walk test results (*Minniti et al., 2009*) High TRV is significantly correlates with inability to walk >300 m in 6 minutes (*Aliyu Zakari et al., 2004*) In men, a history of priapism was also an independent factor associated with PHT (*Gladwin et al., 2004*) These data suggest that PHT represents a component of the systemic vasculopathy of SCD (characterized by systemic hypertension, renal failure and priapism), that it is linked to hemolytic rate, iron overload and cholestatic hepatic dysfunction (*Gladwin et al., 2004*).

There are limited data on the specific management of patients with SCD-PHT. Most of the recommendations are based on expert opinion or extrapolated from data derived from other forms of PHT. The general

approach usually includes maximization of SCD-specific therapy (ie, treatment of primary hemoglobinopathy), treatment of associated cardiopulmonary conditions, general supportive measures and specific therapy for pulmonary hypertension (*Machado & Gladwin., ۲۰۰۵*)

Aim of the work

To determine the prevalence and risk factors of elevated pulmonary artery pressure (clinical and laboratory) in patients with SCD using Doppler echocardiography especially the cardiopulmonary and renal risk factors.

Sickle Cell Disease

Inheritance:

Sickle cell disease (SCD) is an autosomal recessive disorder, characterized by a single base-pair change, thymine for adenine, at the six codon of the β -gene. This change encodes valine instead of glutamine in the sixth position on the β -globin molecule (*Madigan & Malik., ٢٠٠٦*).

Upon deoxygenation, under conditions of hypoxia, acidosis, dehydration, hemoglobin S undergoes conformational changes that expose a hydrophobic region surrounding the valine moiety in the beta-subunit. Polymerization with other hemoglobin tetramers occurs with the formation of long polymer chains that ultimately distort the erythrocyte membrane (*Gladwin & Kato., ٢٠٠٩*).




Fig (١): Inheritance of SCD

(*Bojanowski et al., ٢٠٠٦*)